Payment overview · 2025
General Payments
$1,581.74
103 reported records · 18 companies
Healthcare provider profile · identity verified
James Todd Douglas, M.D.
Allopathic & Osteopathic Physicians|General Practice · BOWLING GREEN, KY · NPI 1790785954
Verified facts
What the public records show
CMS Open Payments records show James Todd Douglas, M.D. received $1,581.74 in general payments during 2025 across 103 reported records.
PFIZER INC. accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Myrbetriq by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 206 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 177 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 176 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $327.87 | 20.7% | 21 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $261.22 | 16.5% | 21 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $181.66 | 11.5% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $163.53 | 10.3% | 10 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $138.14 | 8.7% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $110.91 | 7.0% | 6 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $72.05 | 4.6% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $66.19 | 4.2% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $48.25 | 3.0% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $46.93 | 3.0% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $32.54 | 2.1% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $28.24 | 1.8% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $24.63 | 1.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.27 | 1.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $16.14 | 1.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.44 | 1.0% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $15.37 | 1.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $14.36 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,581.74 | 103 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $276.33 | 18 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $221.58 | 15 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $163.53 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $138.14 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $123.01 | 10 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $123.01 | 10 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $110.91 | 6 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $105.92 | 9 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $89.03 | 5 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $73.47 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $72.05 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $69.74 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $66.19 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $54.75 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.93 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.93 | 5 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $46.93 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $35.57 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $32.54 | 2 | 2025 |
Source payment records
|
|||||
| CLOTTRIEVER BOLD CATHETER Normalized: clottriever bold catheter |
Device | Stryker Corporation | $28.24 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $24.63 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.27 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.44 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $14.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 176 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 206 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 108 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 177 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 144 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
59 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
144 | 34 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
18 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
206 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
26 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
206 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
108 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
177 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
176 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 788 | 186 |
| Levothyroxine Sodium | Levothyroxine Sodium | 671 | 144 |
| Gabapentin | Gabapentin | 567 | 112 |
| Lisinopril | Lisinopril | 497 | 125 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 461 | 110 |
| Metformin Hcl | Metformin Hcl | 436 | 114 |
| Omeprazole | Omeprazole | 428 | 113 |
| Pantoprazole Sodium | Pantoprazole Sodium | 415 | 116 |
| Amlodipine Besylate | Amlodipine Besylate | 383 | 98 |
| Tamsulosin Hcl | Tamsulosin Hcl | 383 | 90 |
| Hydrochlorothiazide | Hydrochlorothiazide | 374 | 92 |
| Losartan Potassium | Losartan Potassium | 363 | 79 |
| Metoprolol Succinate | Metoprolol Succinate | 357 | 80 |
| Alprazolam | Alprazolam | 308 | 48 |
| Furosemide | Furosemide | 283 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 262 | 61 |
| Meloxicam | Meloxicam | 252 | 71 |
| Simvastatin | Simvastatin | 244 | 66 |
| Potassium Chloride | Potassium Chloride | 242 | 59 |
| Glimepiride | Glimepiride | 237 | 50 |
| Sertraline Hcl | Sertraline Hcl | 233 | 57 |
| Montelukast Sodium | Montelukast Sodium | 220 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 216 | 53 |
| Tramadol Hcl | Tramadol Hcl | 209 | 51 |
| Jardiance | Empagliflozin | 206 | 43 |
| Clonazepam | Clonazepam | 203 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 183 | 44 |
| Ozempic | Semaglutide | 177 | 36 |
| Eliquis | Apixaban | 176 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 169 | 44 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 161 | 35 |
| Clopidogrel | Clopidogrel Bisulfate | 159 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 151 | 39 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 146 | 29 |
| Synthroid | Levothyroxine Sodium | 144 | 34 |
| Trazodone Hcl | Trazodone Hcl | 143 | 31 |
| Carvedilol | Carvedilol | 141 | 29 |
| Diazepam | Diazepam | 138 | 22 |
| Fluticasone Propionate | Fluticasone Propionate | 138 | 49 |
| Fluoxetine Hcl | Fluoxetine Hcl | 135 | 28 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 135 | 37 |
| Allopurinol | Allopurinol | 132 | 35 |
| Ondansetron Hcl | Ondansetron Hcl | 127 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 127 | 23 |
| Celecoxib | Celecoxib | 126 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 28 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 119 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 116 | 31 |
| Promethazine Hcl | Promethazine Hcl | 116 | 21 |
| Donepezil Hcl | Donepezil Hcl | 112 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 23 |
| Ezetimibe | Ezetimibe | 109 | 29 |
| Mounjaro | Tirzepatide | 108 | 19 |
| Buspirone Hcl | Buspirone Hcl | 107 | 32 |
| Famotidine | Famotidine | 105 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 101 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 97 | 29 |
| Pregabalin | Pregabalin | 94 | 26 |
| Lorazepam | Lorazepam | 90 | 18 |
| Methocarbamol | Methocarbamol | 89 | 21 |
| Atenolol | Atenolol | 88 | 21 |
| Prednisone | Prednisone | 87 | 46 |
| Bupropion Xl | Bupropion Hcl | 86 | 19 |
| Estradiol | Estradiol | 84 | 17 |
| Topiramate | Topiramate | 82 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 16 |
| Metformin Hcl Er | Metformin Hcl | 79 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 78 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 77 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 74 | 16 |
| Valsartan | Valsartan | 74 | 16 |
| Finasteride | Finasteride | 73 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 70 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 66 | 17 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 63 | 18 |
| Farxiga | Dapagliflozin Propanediol | 61 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 15 |
| Linzess | Linaclotide | 59 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 56 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 56 | 15 |
| Warfarin Sodium | Warfarin Sodium | 56 | suppressed |
| Mirtazapine | Mirtazapine | 55 | 13 |
| Azithromycin | Azithromycin | 54 | 41 |
| Fenofibrate | Fenofibrate | 54 | 13 |
| Spironolactone | Spironolactone | 54 | 18 |
| Amoxicillin | Amoxicillin | 53 | 41 |
| Ondansetron Odt | Ondansetron | 51 | 18 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 49 | suppressed |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 30 |
| Trintellix | Vortioxetine Hydrobromide | 48 | suppressed |
| Memantine Hcl | Memantine Hcl | 46 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 45 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 44 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 13 |
| Verapamil Er | Verapamil Hcl | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | suppressed |
| Brilinta | Ticagrelor | 40 | suppressed |
| Indapamide | Indapamide | 40 | suppressed |
| Naproxen | Naproxen | 40 | 11 |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | suppressed |
| Ramipril | Ramipril | 38 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 38 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 29 |
| Myrbetriq | Mirabegron | 34 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 34 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 34 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 30 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 30 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Ranolazine Er | Ranolazine | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 15 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 28 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 27 | 13 |
| Fluconazole | Fluconazole | 27 | 18 |
| Lovastatin | Lovastatin | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 12 |
| Xarelto | Rivaroxaban | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 26 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Nabumetone | Nabumetone | 26 | suppressed |
| Primidone | Primidone | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | 11 |
| Baclofen | Baclofen | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Cefdinir | Cefdinir | 25 | 23 |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Movantik | Naloxegol Oxalate | 25 | suppressed |
| Nystatin | Nystatin | 25 | 18 |
| Doxycycline Hyclate | Doxycycline Hyclate | 23 | 17 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Hyoscyamine Sulfate | Hyoscyamine Sulfate | 22 | suppressed |
| Ibuprofen | Ibuprofen | 22 | 12 |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 22 | suppressed |
| Ramelteon | Ramelteon | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Rybelsus | Semaglutide | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Hydrocortisone | Hydrocortisone | 21 | 11 |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 17 |
| Cephalexin | Cephalexin | 20 | 13 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Estradiol (Once Weekly) | Estradiol | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 18 | suppressed |
| Felodipine Er | Felodipine | 18 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Prolia | Denosumab | 18 | 12 |
| Varenicline Tartrate | Varenicline Tartrate | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Dofetilide | Dofetilide | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 15 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 15 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 14 | suppressed |
| Chlordiazepoxide-Clidinium | Chlordiazepoxide/Clidinium Br | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Glyburide | Glyburide | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 12 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Apriso | Mesalamine | 11 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 11 | suppressed |
| Glyburide Micronized | Glyburide,micronized | 11 | suppressed |
| Nexium | Esomeprazole Magnesium | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,581.74 · 103 records | PFIZER INC. | ABRYSVO, Auvelity, CAPLYTA, CLOTTRIEVER BOLD CATHETER, COMIRNATY, Cologuard Collection Kit, ELIQUIS, ENTRESTO, Heplisav-B, JARDIANCE, KISUNLA, Kerendia, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, REXULTI, Rybelsus, SHINGRIX, SYNTHROID, UBRELVY, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error